Becker Muscular Dystrophy (BMD) is a rare X-linked recessive neuromuscular disorder frequently caused by in-frame deletions in the DMD gene that result in the production of a truncated, yet functional, dystrophin protein. The consequences of BMD-causing in-frame deletions on the organism are difficult to predict, especially in regard to long-term prognosis. Here, we employed CRISPR-Cas9 to generate a new Dmd del52-55 mouse model by deleting exons 52-55, resulting in a BMD-like in-frame deletion. To delineate the long-term effects of this deletion, we studied these mice over 52 weeks by performing histology and echocardiography analyses and assessing motor functions. Our results suggest that a truncated dystrophin is sufficient to maintain wildtype-like muscle and heart histology and functions in young mice. However, the truncated protein appears insufficient to maintain normal muscle homeostasis and protect against exercise-induced damage at 52 weeks. To further delineate the effects of this exon52-55 in-frame deletion, we performed RNA-Seq pre- and post-exercise and identified several differentially expressed pathways that reflect the abnormal muscle phenotype observed at 52 weeks in the BMD model.
Generation and characterization of a novel mouse model of Becker Muscular Dystrophy with a deletion of exons 52 to 55
Open Access
- Award Group:
- Funder(s): Canadian Institutes of Health Research
- Award Id(s): 6210100686
- Funder(s):
- Split-screen
- Views Icon Views Open Menu
- Open the PDF for in another window
-
Article Versions Icon
Versions
- Accepted Manuscript 05 August 2024
- Share Icon Share
-
Tools Icon
Tools
Open Menu
- Search Site
Lucie O. M. Perillat, Tatianna W. Y. Wong, Eleonora Maino, Abdalla Ahmed, Ori Scott, Elzbieta Hyatt, Paul Delgado-Olguin, Shagana Visuvanathan, Evgueni A. Ivakine, Ronald D. Cohn; Generation and characterization of a novel mouse model of Becker Muscular Dystrophy with a deletion of exons 52 to 55. Dis Model Mech 2024; dmm.050595. doi: https://doi.org/10.1242/dmm.050595
Download citation file:
Advertisement
Cited by
Call for papers – In Vitro Models of Human Disease to Inform Mechanism and Drug Discovery

We invite you to submit your latest research to our upcoming special issue: In Vitro Models of Human Disease to Inform Mechanism and Drug Discovery, coordinated by DMM Editor Vivian Li (The Francis Crick Institute, London, UK), alongside Guest Editors Austin Smith (University of Exeter, UK) and Joseph Wu (Stanford University School of Medicine, USA).The deadline for submitting articles is 6 October 2025.
The Company of Biologists Workshops

For the last 15 years, our publisher, The Company of Biologists, has provided an apt environment to inspire biology and support biologists through our Workshops series. Read about the evolution of the Workshop series and revisit JEB's experience with hosting the first Global South Workshop.
Read & Publish Open Access publishing: what authors say

We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Fast & Fair peer review

Our sister journal Biology Open has recently launched the next phase of their Fast & Fair peer review initiative: offering high-quality peer review within 7 working days. To learn more about BiO’s progress and future plans, read the Editorial by Daniel Gorelick, or visit the Fast & Fair peer review page.
Propose a new Workshop for 2027

We are currently seeking proposals for Workshops to be held in 2027. As one of the scientific organisers of a The Company of Biologists Workshop, your involvement will be focused on interdisciplinary, cutting-edge science and promoting new partnerships and collaborations. We focus on the logistics. Are you thinking about proposing a topic for one of our Workshops? Apply by Friday 30 May 2025.
Other journals from
The Company of Biologists